Třicátý pátý ročník časopisu Klinická farmakologie a farmacie

Karel Urbánek

Klin Farmakol Farm. 2021;35(1):3  

Clinical pharmaceutical care engagement at the Department of Infectious Diseases during the first COVID-19 pandemic wave - single centre experience

Martina Maříková, Věra Josková, Petra Halvová, Petra Rozsívalová, Jaroslav Kapla

Klin Farmakol Farm. 2021;35(1):6-11 | DOI: 10.36290/far.2021.001  

Introduction: The aim of clinical pharmacist medication review and clinical pharmaceutical care as such is the provision of effective and safe pharmacotherapy, the minimization and elimination of risks associated with the use and administration of drugs to a patient. Based on a systematic evaluation of pharmacotherapy, adverse drug reactions, drug interactions, and dose adjustments of drugs in patients with renal or hepatic insufficiency are assessed. Methods: This is a retrospective analysis of the provision of clinical pharmaceutical care for patients hospitalized at the Department of Infectious Diseases in University Hospital Hradec Králové during...

Pharmacokinetic and pharmacodynamic interactions of antiepileptic drugs

Milan Grundmann, Ivana Kacířová

Klin Farmakol Farm. 2021;35(1):12-18 | DOI: 10.36290/far.2021.002  

Approximately 30 % of patients with epilepsy are refractory to monotherapy and are invariably prescribed two or more antiepileptic drugs to control seizures. Because of the long-term nature of epilepsy treatment, it is inevitable that patients will be prescribed nonepilepsy drugs to treat comorbidities. Furthermore, patients with epilepsy may use over-the-counter medications. For these reasons, the propensity of drug-drug interactions is high.

Importance of antiepileptic drugs interactions in routine clinical practice

Ivana Kacířová, Milan Grundmann

Klin Farmakol Farm. 2021;35(1):19-23  

The propensity of drug-drug interactions in antiepileptic drugs is high. The outcome either may be beneficial, if the therapeutic potency of the drug is enhanced, or harmful if the interaction causes an increase in the adverse effects of the drug or if a reduction in efficacy occurs. It is difficult to predict the full extent of drug interactions because of the large interindividual variation between patients. Therapeutic drug monitoring has been used as a tool to optimize therapy regimens for individual patient with epilepsy.

Analytical methods for the determination of cefazolin

Vendula Kubíčková, Zuzana Rácová

Klin Farmakol Farm. 2021;35(1):24-28  

Cefazolin is a broad-spectrum antibiotic used primarily as a prophylactic care for patients during surgery. In specific groups of patients, we encounter variability in pharmacokinetics from the population average. To optimize dosing regimens, reliable bioanalytical methods capable of rapid sample determination should be used. Currently, the most widely used method for measuring plasma concentrations is liquid chromatography with UV or MS detection. Protein precipitation and solid phase extraction can be used for pre-analytical sample preparation. Equilibrium dialysis or ultrafiltration can be used if the free fraction needs to be determined. Undesirable...

A current look at pneumococcal vaccination in adults: why not forget the conjugate vaccine?

Štefan Laššán, Monika Laššánová

Klin Farmakol Farm. 2021;35(1):29-34  

Invasive pneumococcal disease (IPO) and community-acquired pneumonias (CAP) caused by Streptococcus pneumoniae increase morbidity and mortality in the elderly. The most significant progress in the fight to reduce the mortality of IPO and CAP has been achieved mainly through the introduction of pneumococcal vaccination. There are currently available two pneumococcal vaccines: a 23-valent pneumococcal simple polysaccharide vaccine (PPV23), and a 13-valent pneumococcal conjugate vaccine (PCV13). Both vaccines cover the majority of the Pneumococcus serotypes involved in CAP pathogenesis. Currently, some recent studies suggest that vaccination, particularly...

Durvalumab in the treatment of non-small cell lung lung cancer

Ondřej Bílek

Klin Farmakol Farm. 2021;35(1):35-39  

Non-small cell lung cancer (NSCLC) is in most of cases diagnosed as an advanced stage of the disease. Immunotherapy with anti-PD-1 and PD-L1 check-point inhibitors is currently a standard modality of the treatment algorithm. Durvalumab is a fully humanized IgGκ anti-PD-L1 monoclonal antibody. This article goal is to summarize the therapeutic results of durvalumab in NSCLC treatment.

A Case of Ceftriaxone‑Induced Biliary Pseudolithiasis

Timea Taschová, Martin Zápalka, Kamila Michálková, Karel Urbánek

Klin Farmakol Farm. 2021;35(1):40-42 | DOI: 10.36290/far.2021.007  

The report presents a case of a 13-year-old boy treated for Borrelia meningitis with i.v. ceftriaxone at a dose of 50 mg/kg. On the fifth day of therapy, abdominal pain occurred and the presence of concrements in the gallbladder was proven by ultrasonography. The symptoms resolved within one day and the subsequent ultrasound findings after 3 months with ursodeoxycholic acid treatment was completely normal. The cause of the symptoms was ceftriaxone-induced pseudolithiasis due to the precipitation of the antibiotic at very high concentrations in the gallbladder with calcium.

prof. MUDr. František Perlík, DrSc.

Ondřej Slanař

Klin Farmakol Farm. 2021;35(1):43